Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy

Objectives: Second-line therapy for relapsed or refractory acute myeloid leukemia (R/R AML) involves either intensive chemotherapy (ICT) or azacitidine and venetoclax (AZAVEN), but their comparative infectious risks are not well established. Methods: This retrospective multicenter study evaluated in...

Descripció completa

Dades bibliogràfiques

Autors principals:	Maxime Bobo, Lucas Lefevre, Paul Mallet-Guy, Aurelia Chacon, Martin Eloit, Patrice Chevallier, Pierre Peterlin, Jean-Baptiste Mear, Tony Marchand, Maria-Pilar Gallego-Hernanz, Chama Mokeddem, Emmanuel Gyan, Aline Tanguy-Schmidt, Nicolas Vallet
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-03-01
Col·lecció:	International Journal of Infectious Diseases
Matèries:	AML Hypomethylating agent Venetoclax Intensive chemotherapy Infection Febrile neutropenia
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1201971226000470
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!